

Drugs@FDA: FDA-Approved Drugs

f **SHARE** ([HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021462](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021462))

t **TWEET** ([HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=DRUGS@FDA: FDA-APPROVED DRUGS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021462](https://twitter.com/intent/tweet?text=Drugs@FDA: FDA-Approved Drugs&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021462))

in **LINKEDIN** ([HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021462&TITLE=DRUGS@FDA: FDA-APPROVED DRUGS&SOURCE=FDA](https://www.linkedin.com/sharearticle?mini=true&url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021462&title=Drugs@FDA: FDA-Approved Drugs&source=fda))

@ **PIN IT** ([HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON/?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021462&DESCRIPTION=DRUGS@FDA: FDA-APPROVED DRUGS](https://www.pinterest.com/pin/create/button/?url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021462&description=Drugs@FDA: FDA-Approved Drugs))



✉ **EMAIL** ([MAILTO:?SUBJECT=DRUGS@FDA: FDA-APPROVED DRUGS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS&APPLNO=021462](mailto:?subject=Drugs@FDA: FDA-Approved Drugs&body=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021462))



PRINT

[Home \(index.cfm\)](#) | [Previous Page](#)

New Drug Application (NDA): 021462

Company: LILLY

✉ **EMAIL** ([MAILTO:?SUBJECT=DRUGS@FDA: FDA APPROVED DRUG PRODUCTS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/DAF/INDEX.CFM?EVENT=OVERVIEW.PROCESS%26VARAPPLNO=021462](mailto:?subject=Drugs@FDA: FDA Approved Drug Products&body=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process%26varapplno=021462))

- **Other Important Information from FDA**
(<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110261.htm>)
- **Questions and Answers**
(<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110262.htm>)

Products on NDA 021462

CSV	Excel	Print			
Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TEC Code
ALIMTA	PEMETREXED DISODIUM	EQ 500MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription	None
ALIMTA	PEMETREXED DISODIUM	EQ 100MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription	None

Showing 1 to 2 of 2 entries

Approval Date(s) and History, Letters, Labels, Reviews for NDA 021462 **Labels for NDA 021462**